<DOC>
	<DOCNO>NCT02160106</DOCNO>
	<brief_summary>The phase I dose escalation study investigate safety , tolerability , pharmacokinetics TGF-β pathway inhibitor TEW 7197 subject advance , refractory solid tumor .</brief_summary>
	<brief_title>First Human Dose Escalation Study TEW-7197 Subjects With Advanced Stage Solid Tumors</brief_title>
	<detailed_description>This open-label , multicenter , dose-escalation , phase I study TEW-7197 subject advance solid tumor . The study investigate safety , tolerability , pharmacokinetics TEW-7197 , define maximum tolerate dose ( MTD ) TEW-7197 use 3 + 3 design . An expansion phase MTD identify recommend phase 2 dose , emphasis subject melanoma , breast cancer , hepatocellular carcinoma , prostate cancer . TEW-7197 orally bioavailable small molecule inhibits protein serine/threonine kinase activin receptor-like kinase 5 ( ALK5 ) block intracellular signal TGF-β inhibit phosphorylation ALK5 substrates .</detailed_description>
	<criteria>Advanced stage solid tumor document histological cytological evidence , available approved therapy know cure metastatic disease extend survival , receive standard therapy . Documented disease progression follow prior therapy , assess Investigator . Eastern Cooperative Oncology Group ( ECOG ) 0 1 . Evaluable measurable disease define RECIST v1.1 may enrol dose escalation part ; dose confirmation part , subject must measurable disease RECIST v1.1 biomarker response . Males females ≥ 18 year age . Able give write informed consent . Able swallow tablet . Willing able comply schedule visit , treatment plan , laboratory test procedure . Acceptable liver function : Bilirubin ≤ 1.5 time upper limit normal ( ULN ) , Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) ≤ 3 time ULN ; liver metastases present , ≤ 5 time ULN allow . Acceptable renal function : *Serum creatinine ≤ 1.5 time ULN . Acceptable hematologic status ( without growth factor support transfusion dependency ) : Absolute neutrophil count ( ANC ) ≥ 1,500 cells/μL , Platelet count ≥ 100,000/μL , Hemoglobin ≥ 9.0 g/dL . QTc interval calculate accord Fridericia 's formula ( QTcF = QT/RR0.33 ; RR = RR interval ) ≤ 450 msec screen electrocardiogram ( ECG ) . Must normal ejection fraction ( within reference range institution ) clinically significant valvular dysfunction . Must discontinue cancer treatment , include experimental agent 28 day minimum 5 halflives ( biologics ) prior start treatment . Enrollment exposure level biologic fall active level establish summary basis approval acceptable . Must discontinue radiotherapy least 14 day resolution toxicity Grade 1 good prior start treatment . A life expectancy least 3 month assess Investigator . Female subject childbearing potential must negative serum pregnancy test within 7 day first administration study drug . For purpose study , female subject childbearing potential define female subject puberty unless postmenopausal least 1 year , surgically sterile ( hysterectomy bilateral oophorectomy tubal ligation ) . Elevated Troponin 1 level screen know persistently elevate brain natriuretic peptide ( BNP ) . Serious preexist medical condition follow : Myocardial infarction within 6 month prior screen , pericardial effusion , History cardiac aortic surgery , Serious arrhythmia , Unstable angina pectoris , Congestive heart failure New York Heart Association class III/IV , Hypertension control standard medication ( 150/90 mmHg ) , Cirrhosis liver , ChildPugh Stage B C , history liver transplant , Severe diabetes currently control , Current history interstitial pneumonitis , Presence aneurisms ascend aorta aortic stress . Uncontrolled metastatic disease brain central nervous system ( CNS ) . Known history difficulty swallowing , malabsorption condition may reduce absorption product . Received prior treatment target signal pathway TGFβ . Major abnormality identify ECG echocardiogram ( ECHO ) , Investigator 's discretion . Known infection , test positive , human immunodeficiency virus , hepatitis B virus hepatitis C virus . Active infection require systemic antibiotic therapy . Known substance abuse receive concurrent treatment nonpermitted drug . Female subject breastfeeding , intend breastfeed duration study 30 day follow last dose study drug . Known history , suspect hypersensitivity excipients . Female subject must pregnant risk become pregnant study . Fertile male female subject must agree use effective barrier method birth control avoid pregnancy ( female subject doublebarrier method contraception , male subject condom spermicide ) total abstinence time provide informed consent 90 day last administration study drug . Use oral contraceptive allow . Any serious medical condition Investigator 's opinion would preclude safe participation study . Subjects , opinion Investigator , unsuitable participate study . Currently use plan use : Drugs exclusively primarily eliminate cytochrome P450 isozyme 3A4 ( CYP ) 3A4 . Drugs exclusively primarily eliminate UDP glucuronyltransferase 1A1 ( UGT ) 1A1 . Drugs substrates drug transporter multidrug resistance protein 1 ( MDR1 ) narrow therapeutic window ; strong inhibitor drug transporter MDR1 . Any major surgery within 28 day .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Cancer</keyword>
	<keyword>advanced solid tumor</keyword>
	<keyword>metastatic</keyword>
	<keyword>phase I</keyword>
	<keyword>transform growth factor beta</keyword>
	<keyword>TGF-β</keyword>
	<keyword>first-in-human</keyword>
	<keyword>TEW-7197</keyword>
	<keyword>activin receptor-like kinase 5</keyword>
	<keyword>ALK5</keyword>
	<keyword>Smad2</keyword>
	<keyword>Smad3</keyword>
	<keyword>phospho-Smad</keyword>
	<keyword>phospho Smad</keyword>
	<keyword>psmad</keyword>
	<keyword>serine / threonine kinase inhibitor</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>MedPacto</keyword>
	<keyword>National OncoVenture</keyword>
</DOC>